Ardelyx’s (ARDX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ardelyx (NASDAQ:ARDX) in a report released on Friday, Benzinga reports. The firm currently has a $11.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ardelyx’s Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2026 earnings at $0.58 EPS.

Several other brokerages also recently issued reports on ARDX. StockNews.com raised shares of Ardelyx from a “sell” rating to a “hold” rating in a research report on Wednesday, July 31st. Citigroup raised their price target on Ardelyx from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Ardelyx in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Ardelyx Stock Up 3.7 %

Ardelyx stock opened at $6.09 on Friday. The company has a market capitalization of $1.43 billion, a P/E ratio of -20.30 and a beta of 0.92. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.99 and a current ratio of 4.21. Ardelyx has a fifty-two week low of $3.43 and a fifty-two week high of $10.13. The stock has a 50-day simple moving average of $6.07 and a 200-day simple moving average of $6.32.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $73.20 million during the quarter, compared to the consensus estimate of $55.03 million. Ardelyx had a negative return on equity of 46.86% and a negative net margin of 28.82%. The company’s revenue was up 228.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.08) earnings per share. Equities research analysts expect that Ardelyx will post -0.25 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michael Raab sold 25,000 shares of Ardelyx stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $5.91, for a total value of $147,750.00. Following the sale, the chief executive officer now directly owns 1,210,108 shares in the company, valued at $7,151,738.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Michael Raab sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $5.91, for a total value of $147,750.00. Following the completion of the sale, the chief executive officer now owns 1,210,108 shares in the company, valued at $7,151,738.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David P. Rosenbaum sold 20,000 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $5.94, for a total transaction of $118,800.00. Following the transaction, the insider now owns 356,479 shares in the company, valued at $2,117,485.26. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 212,126 shares of company stock valued at $1,298,963 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Ardelyx

Several hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its position in shares of Ardelyx by 347.4% during the 1st quarter. Principal Financial Group Inc. now owns 122,811 shares of the biopharmaceutical company’s stock worth $897,000 after purchasing an additional 95,361 shares during the last quarter. Swiss National Bank boosted its stake in shares of Ardelyx by 6.7% during the 1st quarter. Swiss National Bank now owns 458,300 shares of the biopharmaceutical company’s stock worth $3,346,000 after purchasing an additional 28,900 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Ardelyx by 100.7% during the first quarter. Russell Investments Group Ltd. now owns 536,297 shares of the biopharmaceutical company’s stock worth $3,915,000 after buying an additional 269,046 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Ardelyx by 8.9% in the first quarter. ProShare Advisors LLC now owns 57,729 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 4,735 shares during the last quarter. Finally, Entropy Technologies LP purchased a new position in shares of Ardelyx during the first quarter valued at approximately $341,000. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.